Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 2Terminated 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 7Genitourinary 6Myeloid 5Thoracic 4Head & Neck 3Gastrointestinal 2Breast 2Tumor-Agnostic 1Sarcoma 1Plasma cell 1Endocrine 1Dermatologic 1CNS 1

Conditions

Leukoplakia, Oral 2Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Head and Neck Neoplasms 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pioglitazone × Head & Neck × Clear all
NCT00099021 2022-02-11

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 6 charts
Head & Neck

Head and Neck Neoplasms, Leukoplakia, Oral

NCT01655719 2017-10-26

Pioglitazone in Thyroid Cancers

University of Michigan

Phase 2 Completed
1 enrolled 6 charts
EndocrineHead & Neck

Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene

NCT00951379 2016-04-06

Pioglitazone for Oral Premalignant Lesions

National Cancer Institute (NCI)

Phase 2 Terminated
52 enrolled 23 charts
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡